MedTrace Logo

Amifostine for Head and Neck Irradiation in Lymphoma

NCT00136474 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2009-11-02

No results posted yet for this study

Summary

The purpose of this study is determine the effects (good and bad) amifostine has on radiation-induced side effects of lymphoma treatment.

Conditions

  • Lymphoma
  • Hodgkin's Disease
  • Non-Hodgkin's Lymphoma

Interventions

DRUG

Amifostine

Given 30-60 minutes prior to daily radiation therapy

RADIATION

Radiation Therapy

Daily radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Andrea K. Ng, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2005-05-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00136474 on ClinicalTrials.gov